Clinical Trials Logo

Clinical Trial Summary

The United Kingdom has a high prevalence of asthma (over 12%) and some of the worst health outcomes in Europe. The management of respiratory disease and associated patient outcomes has long been an area of focus and improvement for the National Health Service. With the advancement of digital health technology, there is the potential to transform patient care and improve outcomes. The Aptar Digital Health respiratory disease management platform, a digital therapeutic will be utilized to determine its value and how it supports: i) asthma patient engagement and facilitates communication between patients and providers to accelerate medication adherence; ii) asthma control through the use of the Asthma Control Questionnaire-5. In addition, spirometry and fractioned exhaled nitric oxide will be utilized during the study to validate and enhance current National Institute for Health and Care Excellence guidelines.


Clinical Trial Description

This is an open-label, single comparative study that will accrue a total of 118 participants and compare pre and post study results. Group # 1 will consist of 59 participants with a fractioned exhaled nitric oxide ≥ 45 ppb and ≥ 3 exacerbations / year (biologic eligible). Group # 2 will consist of 59 participants with a fractioned exhaled nitric oxide ≥ 45 ppb and < 3 exacerbations / year (non-biologic eligible). At the baseline visit, clinic appointment # 1, health care providers will review the participants' medical records to determine clinical outcomes in the past year, including number of exacerbations, medication pharmacy refill percentage, and fractioned exhaled nitric oxide score. At the baseline visit, participants will also complete the Asthma Control Questionnaire-5 and the Mini-Asthma Quality of Life Questionnaire. The past year clinical evaluation and Asthma Control Questionnaire-5 and Mini-Asthma Quality of Life Questionnaire will be considered baseline results. Patients will be screened for study appropriateness at the Guy's Hospital Severe Asthma Clinic. During the initial visit, which will be considered the study baseline visit, patients will be provided with the Aptar Digital Health respiratory disease management platform and trained to use the platform. Participants will be scheduled for in person follow-up visits at 1-2 months and then 6-months post-baseline; patients will be scheduled for virtual visits at 3-months post-baseline. Patients will then be trained by Guy's Hospital team members; Aptar Digital Health staff will provide extensive training to the Guy's Hospital team prior to the study to ensure the team is fully knowledgeable about the product, its features, and can successfully onboard participants onto the Aptar Digital Health respiratory disease management platform. Once participants are trained, they will utilize the BreatheSmart mobile application by downloading it through either the Apple Store™ or Google Play™. The BreatheSmart mobile application records, stores, and transmits usage events to the HeroTracker sensors, or via manual user entry, to a remote storage system. Participants may self-enter their medication schedule either with or without the help of their health care providers. Through the BreatheSmart mobile application, they can review information collected from the HeroTracker Sense metered dose inhaler and FindAir ONE dry powder inhaler sensors, report and review their adherence and self-reported symptoms, and answer validated questionnaires. Participants can share the data entered through the BreatheSmart mobile application with caregivers and health care providers. Health care providers are then able to utilize BreatheSmart Connect, a web application, to obtain an overview of all participants utilizing the Aptar Digital Health respiratory disease management platform including detailed views of individual participant information. Health care providers can view real-time adherence, medication list, participants within and outside of risk zones (depending on adherence), rescue medication usage, symptoms, and triggers. Based on the information gleaned from the BreatheSmart Connect platform, clinicians will schedule follow-up participant appointments with either a junior or senior pharmacist at the Guy's Hospital Severe Asthma Clinic. Participants will use the Aptar Digital Health respiratory disease management platform for 6 months and will be required to return the device upon study completion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06364527
Study type Interventional
Source CoheroHealth
Contact Akash Bijlani, MPH
Phone 6502489166
Email akash.bijlani@aptar.com
Status Not yet recruiting
Phase N/A
Start date May 2024
Completion date November 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Recruiting NCT04693975 - Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases
Completed NCT04456270 - Asthma Control in a Dutch Primary Care Population
Active, not recruiting NCT04593394 - Inducible Laryngeal Obstruction in Severe Asthma in Severe Asthma
Not yet recruiting NCT03879590 - Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma Phase 3
Recruiting NCT04613245 - Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19
Withdrawn NCT05304494 - Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
Completed NCT03498742 - Asthmatic Subjects Could Live Without Short Acting beta2 Agonists
Recruiting NCT05572177 - Feasibility of a Smartphone Application for Asthma Self-management N/A
Not yet recruiting NCT05841901 - Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma N/A
Not yet recruiting NCT04799678 - Pilot Voice Sample Collection From People With Asthma
Not yet recruiting NCT06273072 - Metformin IN Asthma for Overweight and Obese Individuals (MINA) Phase 2
Terminated NCT03736629 - Azithromycin Treatment for the Airway Microbiome in Asthma Phase 2
Recruiting NCT03788057 - Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma N/A
Not yet recruiting NCT02283008 - Inhaler Technique Training N/A
Completed NCT02227394 - Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients Phase 2
Not yet recruiting NCT05432440 - Evaluation of Pharmacist-guided Digital-based Asthma Education for Indonesian Children With Asthma N/A
Completed NCT05270278 - Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
Completed NCT03642418 - User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
Recruiting NCT05609760 - Pictograms to Facilitate Comprehension of Medical Indications N/A